Search and analyze individual stocks with comprehensive metrics

Sai Life Sciences Ltd

SAILIFEPharmaceuticals
872.20+0.00 (+0.00%)
As on 16 Jan 2026, 10:14 amMarket Closed

Fundamental Score

...

Sai Life Sciences Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

11.05%
Poor

Return on Capital Employed

14.05%
Excellent

Operating Profit Margin (5Y)

19.31%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

64.17x

Market Capitalization

18.38K (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

101.98%
Excellent

YoY Quarterly Sales Growth

35.88%
Excellent

Sales Growth (5Y)

18.49%

EPS Growth (5Y)

N/A
Excellent

Profit Growth (5Y)

17.57%

Financial Health

Excellent

Debt to Equity

0.18x
Excellent

Interest Coverage

7.88x
Poor

Free Cash Flow (5Y)

-224.76 (Cr)

Ownership Structure

Average

Promoter Holding

34.93%
Excellent

FII Holding

22.49%
Excellent

DII Holding

29.95%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Mid-cap
Balance of growth potential and stability.
34.93%
Promoter Holding
18.38K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of SAILIFE across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Operating Margins (19.31%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Robust Profit Growth (101.98%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (35.88%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Consistent Growth Track Record (18.49% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.

Strong Profit Growth Track Record (17.57% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Conservative Debt Levels (D/E: 0.18)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (7.88x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Institutional Confidence (FII+DII: 52.44%)

Observation: Significant professional investor participation indicates quality recognition.

Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

5 factors identified

Premium Valuation Risk (P/E: 64.17x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Negative Free Cash Flow (₹-224.76 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Sai Life Sciences Ltd

About SAILIFE

Business Overview

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.

Company Details

Symbol:SAILIFE
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Ranga Raju Kanumuri
Executive Chairman
Mr. Krishnam Raju Kanumuri
CEO, MD & Executive Director
Mr. Sivaramakrishnan Chittor
CFO & Whole Time Director

SAILIFE Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)11.05%
Return on Capital Employed14.05%
Operating Profit Margin (5Y)19.31%
Debt to Equity Ratio0.18
Interest Coverage Ratio7.88

Growth & Valuation

Sales Growth (5Y)18.49%
Profit Growth (5Y)17.57%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth101.98%
YoY Quarterly Sales Growth35.88%

Frequently Asked Questions

What is the current price of Sai Life Sciences Ltd (SAILIFE)?

As of 16 Jan 2026, 10:14 am IST, Sai Life Sciences Ltd (SAILIFE) is currently trading at ₹872.20. The stock has a market capitalization of ₹18.38K (Cr).

Is SAILIFE share price Overvalued or Undervalued?

SAILIFE is currently trading at a P/E ratio of 64.17x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Sai Life Sciences Ltd share price?

Key factors influencing SAILIFE's price include its quarterly earnings growth (Sales Growth: 35.88%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Sai Life Sciences Ltd a good stock for long-term investment?

Sai Life Sciences Ltd shows a 5-year Profit Growth of 17.57% and an ROE of 11.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing.

How does Sai Life Sciences Ltd compare with its industry peers?

Sai Life Sciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare SAILIFE's P/E of 64.17x and ROE of 11.05% against the industry averages to determine its competitive standing.

What is the P/E ratio of SAILIFE and what does it mean?

SAILIFE has a P/E ratio of 64.17x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹64 for every ₹1 of annual earnings.

How is SAILIFE performing according to Bull Run's analysis?

SAILIFE has a Bull Run fundamental score of 48.6/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does SAILIFE belong to?

SAILIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sai Life Sciences Ltd.

What is Return on Equity (ROE) and why is it important for SAILIFE?

SAILIFE has an ROE of 11.05%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Sai Life Sciences Ltd generates profits from shareholders' equity.

How is SAILIFE's debt-to-equity ratio and what does it indicate?

SAILIFE has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is SAILIFE's dividend yield and is it a good dividend stock?

SAILIFE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has SAILIFE grown over the past 5 years?

SAILIFE has achieved 5-year growth rates of: Sales Growth 18.49%, Profit Growth 17.57%, and EPS Growth N/A%.

What is the promoter holding in SAILIFE and why does it matter?

Promoters hold 34.93% of SAILIFE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is SAILIFE's market capitalization category?

SAILIFE has a market capitalization of ₹18379 crores, placing it in the Mid-cap category.

How volatile is SAILIFE stock?

SAILIFE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for SAILIFE?

SAILIFE has a 52-week high of ₹N/A and low of ₹N/A.

What is SAILIFE's operating profit margin trend?

SAILIFE has a 5-year average Operating Profit Margin (OPM) of 19.31%, indicating the company's operational efficiency.

How is SAILIFE's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 35.88% and YoY Profit Growth of 101.98%.

What is the institutional holding pattern in SAILIFE?

SAILIFE has FII holding of 22.49% and DII holding of 29.95%. Significant institutional holding often suggests professional confidence in the stock.